Tuberculosis drugs market

Tuberculosis Drugs Market, by Therapy Type (First Line Therapy, and Second Line Therapy), by Disease type (Active TB, and Latent TB), by End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2019 – 2027

Request Free Sample

Sep 2019
CMI191
198 Pages
Excel & Pdf
Pharmaceutical

Summary

Tuberculosis Drugs Market – Insights

Tuberculosis (TB) is a chronic condition, and has become a global disease burden. Manufacturers of TB drugs are focused on developing drugs that can shorten the duration of treatment, and help to overcome challenges of drug-susceptible TB and drug-resistant TB. The treatment of TB is divided into two types, such as first line treatment, second line treatment, and drug resistant treatment.

Advanced technologies and introduction of novel therapies are expected to improve the duration of treating TB, however, most TB cases with currently available medicines can require up to 6 months of treatment. However, despite of existing medicines and ongoing TB treatment drugs innovations, there is continuous need to improve patients’ access to appropriate TB medicines particularly in the areas of multidrug-resistant TB (MDR TB) and pediatric TB.

The global tuberculosis drugs market was valued at US$ 1,146.5 million in 2019, and is expected to exhibit a CAGR of 5.3% over the forecast period (2019 – 2027).

Global Tuberculosis Drugs Market Share (%) Analysis, by Therapy Type, 2019

Source: Coherent Market Insights Analysis (2019)

Increasing R&D Investments and New Drug Developments Are Expected to Drive Growth of the Tuberculosis Drugs Market

Increasing number of drug developments are driving growth of the tuberculosis drugs market. U.S.-based TB Alliance, a nonprofit organization, has developed a new drug for treating highly drug-resistant forms of tuberculosis. For instance, in August 2019, TB Alliance received the U.S. FDA approval for Pretomnid, a combination regimen with bedaquiline and linezolid, which is developed and indicated for the treatment of patients with XDR-TB, or intolerant non-responsive MDR-TB.

Moreover, market players are focusing on strategic collaborations to commercialize their newly developed drugs. For instance, in April 2019, Mylan, a pharmaceuticals company, collaborated with TB Alliance to commercialize the Pretomanid drug for treating pulmonary tuberculosis (TB).

Furthermore, high prevalence of TB across the globe is driving growth of the TB drugs market. For instance, according to WHO’s global tuberculosis report 2018, around 10 million people worldwide suffered from TB in 2017.

Tuberculosis Drugs Market – Restraints

The increasing incidence of drug recall is a major factor restraining the market growth. Manufacturers of TB drug are facing challenges such as increasing product recalls owing to factors such as packaging or manufacturing flaws. For instance, in 2018, Sandoz recalled its batch of wrongly-packed tuberculosis (TB) drugs in India. Furthermore, in 2016, Novartis manufactured a drug Onecure which was recalled by the Philippines Food and Drug Administration for insufficient amount of rifampicin in the drug.

The high pricing of drugs is another factor restraining the growth of the market. Second line treatment drugs are highly priced compared to first line treatment with more side effects and high level toxicity.

Tuberculosis Drugs Market - Regional Insights

On the basis of region, the global tuberculosis drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among region, North America is expected to hold a dominant position in the global tuberculosis drugs market over the forecast period, owing to higher cost of TB drugs in the region. For instance, in 2015, the Cycloserine drug for treating multidrug-resistant tuberculosis, increased its price from US$15 per tablet to US$ 360 per tablet owing to transfer of rights to Rodelis Therapeutics.

The market in Europe is expected to grow over the forecast period, owing to high prevalence of tuberculosis in the region. For instance, according to the TB Europe Coalition, in 2015, about 323,000 new TB cases and 32,000 deaths were reported in Europe.

Global Tuberculosis Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Source: Coherent Market Insights Analysis (2019)

Tuberculosis Drugs Market - Competitive Landscape

Major players operating in the global tuberculosis drugs market include Johnson & Johnson Services, LLC, Lupin Ltd, Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., and others.

Table of Content

Table of Contents

*Browse 28 market data tables and 33 figures on “Tuberculosis Drugs Market” - Global forecast to 2027”

N/A

- Frequently Asked Questions -

What are the growth estimates for tuberculosis drugs market till 2027?

The global tuberculosis drugs market is estimated to surpass US$ 1,651.2 Million by 2027.

Which are the prominent tuberculosis drugs market players across the globe?

What are the key factors hampering growth of the tuberculosis drugs market?

Increasing incidence of drug recall is one of the major factors that is expected to hamper growth of the market over the forecast period.

What are the key factors driving growth of the tuberculosis drugs market?

Increasing number of drug developments is one of the major factors that is expected to propel growth of the market over the forecast period.

What is the Compound Annual Growth Rate (CAGR) of the tuberculosis drugs market for next 8 years?

The global tuberculosis drugs market is estimated to exhibit a CAGR of 5.3% over the forecast period.

Which region is dominating the tuberculosis drugs market growth?

Among regions, North America is expected to hold a dominant position in the global tuberculosis drugs market over the forecast period.